Reply to The atypical Spitz tumor of uncertain biologic potential by Ludgate, Mathew W. et al.
The Atypical Spitz Tumor of
Uncertain Biologic Potential
A Series of 67 Patients From a
Single Institution
I read with interest the recent article by Ludgate et al,1
who reported on a large series of atypical Spitz tumors
(ASTs), a subgroup of ambiguous tumors that have histo-
logic features of Spitz nevi mixed with features of mela-
noma and, thus, are difficult to diagnose. In such patients,
sentinel node biopsy has been proposed with the hypothe-
sis that, if any metastasis is detected, then it represents
proof that the lesion was malignant. To date, 117 patients
with ASTs who underwent sentinel node biopsy have
been reported, and 50 of those patients had lymph node
lesions.1 Such melanocytic deposits have been interpreted
mostly as micrometastases; however, because the possibility
that they represent only benign nevi also was considered, the
consequent discussion developed by the authors on this topic
risks diminishing the possible diagnostic value of sentinel
node biopsy in patients with these tumors.
Undoubtedly, the incidence of melanocytic deposits
in sentinel lymph nodes from patients with ASTs (42.7%)
differs dramatically from that of lymph node nevi in senti-
nel lymph nodes from patients with melanoma (3.9%).2
However, because diagnostic criteria with which to differ-
entiate lymph node micrometastases from lymph node
nevi exist and seem to work,2 all lymph node lesions
should be diagnosed using the same histologic criteria,
irrespective of the diagnoses made on synchronous cuta-
neous tumors. In fact, it does not seem reasonable to diag-
nose a lymph node lesion as metastasis if the cutaneous
lesion was labeled as melanoma and to diagnose a lymph
node lesion that has the same characteristics differently if
the cutaneous tumor was classified otherwise. If to diag-
nose a cutaneous tumor using data derived from a lymph
node is illogical,3 then, in the same way, it must be illogi-
cal to use data derived from a cutaneous tumor to diag-
nose a lymph node lesion.
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We thank Dr. Urso for his comments on a difficult
topic.1 In conventional melanoma, distinguishing be-
tween melanoma micrometastases and benign lymph
node nevi usually is possible based on established criteria.
However, this distinction can be less clear with many rarer
melanocytic lesions, including atypical Spitz tumors
(ASTs). For example, cellular blue nevi may have melano-
cytic deposits within the parenchyma and subcapsular
sinus of lymph nodes, a location typically associated with
conventional metastases.2 Conversely, benign intraparen-
chymal lymph node nevi have been reported in other
benign melanocytic lesions.3 In these patients, the classifi-
cation and features of the primary cutaneous lesion is vital
in determining the nature of the lymph node deposit. If
the lymph node deposits are viewed in isolation, then they
could be interpreted erroneously as malignant metastasis.
We do not know whether conventional Spitz nevi (agreed
on by a consensus of experts as lacking sufficient criteria
for spitzoid melanoma or AST) are capable of a similar
phenomenon of having benign parenchymal or subcapsu-
lar sinus lymph node deposits that mimic malignant
micrometastases, as suggested by LeBoit.4 If this phenom-
enon does occur in conventional Spitz nevi, then the cyto-
logic features of the primary cutaneous lesion become
even more relevant, and it is paramount to evaluate the
cytologic features of the lymph node deposits in the con-
text of the primary lesion. Therefore, although it is
Cancer January 1, 2010 257
Correspondence
possible that many of the lymph node deposits we
observed in ASTs were malignant micrometastases, we
believe that the possibility of a benign process cannot be
entirely excluded. We agree that the incidence of lymph
node positivity in our series of AST is high (47%) com-
pared with the incidence of lymph node nevi (range,
1%-22%) reported in series of conventional mela-
noma.5,6 However, because the incidence of benign
lymph node deposits in conventional Spitz nevi is
unknown (and likely will never be known), the reason
for and significance of this discrepancy is unclear.
Hopefully, future molecular insights in ASTs and their
sentinel lymph node deposits may be able to shed some
light onto their true nature.
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